GayN., EdmundsW., BathE.. Estimating the Global Burden of Hepatitis B.Geneva: World Health Organization, Department of Vaccines and Biologicals, 2001
2.
MargolisH.S., AlterM.J., HadlerS.C.Hepatitis B: evolving epidemiology and implications for control.Semin Liver Dis1991; 11: 84–92
3.
KaneM.A.Global status of hepatitis B immunisation.Lancet1996; 348: 696
4.
Sanchez-TapiasJ.M., VilarJ.H., CostaJ.. Natural history of chronic persistent hepatitis B. Relationship between hepatitis B virus replication and the course of the disease.J Hepatol1984; 1: 15–27
5.
FattovichG.Natural history of hepatitis B.J Hepatol2003; 39: S50–8
LaiC.L., ChienR.N., LeungN.W.. A one-year trial of lamivudine for chronic hepatitis B.N Engl J Med1998; 339: 61–8
10.
MarcellinP., ChangT.T., LimS.G.. Adefovir depivoxil for the treatment of hepatitis B e antigen positive chronic hepatitis B.N Engl J Med2003; 348: 808–16
11.
DienstagJ.L., SchiffE.R., WrightT.L.. Lamivudine as initial treatment for chronic hepatitis B in the US.N Engl J Med1999; 341: 1256–63
12.
EASL Consensus Conference on Hepatitis B.J Hepatol2003; 39: S3–25
13.
LokA.S., ChungH.T., LiuV.W., MaO.C.Long-term follow-up of chronic hepatitis B patients treated with interferon alfa.Gastroenterology1993; 105: 1833–8
14.
VilleneuveJ.P., CondreayL.D., WillemsB.. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.Hepatology2000; 31: 207–10
15.
CooksleyW.G.E., PiratvisuthT., WangY.. 40 KDA peginterferon alfa-2a (PEGASYS(r)): efficacy and safety results from a phase II, randomized, multicenter study in the treatment of HBeAg positive chronic hepatitis B.Hepatology2001; 34: 349A